Hyderabad-based vaccine maker Bharat Biotech on Wednesday introduced that the Central Drugs Standard Control Organization (CDSCO) has authorised a 12-month shelf life extension from the date of manufacture of Covaxin Covid-19 vaccine.
This got here hours earlier than the World Health Organization (WHO) beneficial emergency use listing standing According to PTI on Wednesday for Bharat Biotech’s Covaxin.
“This approval of shelf life extension is based on the availability of additional sustainability data, which was submitted to CDSCO. The shelf life extension has been communicated to our stakeholders,” the corporate stated in a tweet.
#COVAXIN #COVID-19 #BharatBiotech pic.twitter.com/9oPnYnlgtC
– Bharat Biotech (Habharat Biotech) November 3, 2021
Earlier, Australia’s regulator, the Therapeutic Goods Administration (TGA), stated that Covaxin can be “recognized” for the aim of creating the vaccination standing of a traveller”. Many international locations like Greece, Oman, Mauritius and Philippines, amongst others had authorised Covaxin for journey lengthy earlier than WHO approval.
.
With inputs from TheIndianEXPRESS
